Global Hepatitis C Drugs Market Research Report- Forecast to 2030

Hepatitis C Drugs Market Information, By Drug Class (Anti-Viral, Immuno-modulators and others), By Medicine System (Allopathic, Alternative and Others), By Route of Administration (Oral, Injectable and others) and By End User (Hospitals and Private) - Forecast Till 2030

ID: MRFR/Pharma/1848-HCR | February 2021 | Region: Global | 100 pages         

Hepatitis C Drugs Market Speak to Analyst Request a Free Sample

Hepatitis C Drugs Market Overview


Hepatitis C drugs market was valued USD 18700 million and expected to reach USD 281.55 million by the end of forecasting period reflecting a sluggish CAGR of 1.17% by 2030. Hepatitis is inflammation of the liver portrayed by yellowed eyes and skin because of bilirubin, influenza like side effects which incorporate sickness, heaving, unfortunate hunger, joint agony, migraines, hued dirt stools and so on.


Hepatitis is brought about by various variables, both microbial and non-microbial. But hepatitis C is brought about by hepatitis C infection and influences between 130-150 million individuals internationally each extended time, of which roughly 700 000 individuals pass on from hepatitis C-related liver illnesses. What is of more prominent concern is the way that 15 to 20% of persistently tainted patients foster liver cirrhosis or liver malignant growth.


The hepatitis C drugs market size is driven by variables such as illness pervasiveness, ascend in government sponsorship and repayment, particularly in the U.S., more prominent screening, particularly in non-industrial countries, illicit drug use, and hazardous sex so forth.


In any case, the restrictions are overpowering, for example, the self-impersonating nature of the sickness in a sizable number of patients, the challenge of domestic therapy presented at insignificant costs, particularly in creating areas, cost battle between organizations, for example, among Gilead and Merck, rising urbanization and better disinfection and so on.


In this way, the Hepatitis C Drugs Market in created locales seems to arrive at a level as the number of individuals impacted isn't ascending in created districts. The re-assessment of the hepatitis C technique by organizations, for example, Boehringer Ingelheim and its choice to shun pushing ahead in hepatitis C examination, also means dormancy in created locale markets.


The Hepatitis C Drugs Market share is likewise unitary with a couple of predominant players, for example, Gilead with a couple of brands, Sovaldi, Harvoni and so forth, driving the market. The improvement pipeline is solid in the immunization section. It is normal that an antibody will make its invasion sooner rather than later, as occurred with different types of hepatitis.


Covid-19 Analysis:


The effect of COVID-19 on Hepatitis C Drugs Market analysis for the year 2020 with a viral disease brought about by hepatitis C infection (HCV). 


Hepatitis C infection is a blood-borne infection that causes liver illness and can cause intense and ongoing hepatitis. The disease might be caused by infusion drug use, bonding of unscreened blood items, hazardous infusion rehearses, sexual contact and from contaminated mother to her child.


Finding HCV contamination should be possible by evaluating for hostility to HCV antibodies alongside a serological test to affirm the viral disease. Nucleic analysis for HCV ribonucleic corrosive (RNA) is acted if there should arise an occurrence of positive test results for hostile to HCV antibodies to affirm constant contamination.


Since there is no immunization accessible for HCV contamination, the World Health Organization (WHO) prescribes blood tests to screen patients that are at an expanded gamble of HCV disease and lessen the gamble of HCV openness in medical care settings. Screening of pregnant individuals for HCV is the standard of care in many nations and is viewed as a practical technique for decreasing the gamble of transmission to the child.


Market Dynamics



  • Key Market Drivers


Agricultural nations, for example, India, China and Brazil, have an enormous patient pool contrasted with other created nations. This increments interest in hepatitis C treatment drugs. Not many nations and state legislatures have taken drives to control hepatitis C contamination by sponsoring drugs or by giving exceptional assets towards sickness therapy programs. Different private NGOs make mindfulness and teach the populace to help battle the hepatitis C disease. These may likewise be considered drivers for the Hepatitis C treatment market.


The pervasiveness of hepatitis C contamination among people worldwide is expanding. This is fundamentally brought about by sharing needles, unsterilized clinical gear, and blood bonding channels from contaminated mother to newly conceived child.



  • Market Challenges:


In hepatitis C disease treatment, there are around 2300 atoms in pipeline studies and around 300 in stage 4 investigations. Different organizations are engaging in the advancement of hepatitis C treatment prescription. This would prompt the advancement of new items, which eventually drives the Hepatitis C Drugs Market.



  • Market Opportunities


Various nations have different guideline bodies to endorse drugs for illness treatment. Because of this, drugs are not handily supported on the lookout, influencing the accessibility of items on the lookout; as per The United States Attorney General (A.G.), over half of the specialists who endorsed Harvoni were denied inclusion by their guarantor. Protection suppliers deny repayment demands because of the high treatment cost. In addition, payers repay a tiny measure of the all-out cost of the treatment, which eventually diminishes, generally speaking, business sector size.



  • Market Restraints:


The significant expense of drugs is the top restriction for the Hepatitis C Drugs Market, as the cost of the treatment is a lot higher, and everyone can't manage the cost of the treatment. For instance, the cost of Harvoni (Ledipasvir and Sofosbuvir) medication is US$ 94,500 for a 12-week treatment, which is around US$ 1100 for each pill. Rigid administrative standards prevent early endorsements and crash commercialization of items, which eventually hampers market development.


Market Segmentation:


On the basis of drug class which comprises anti-viral, immuno-modulators and others. On the basis of the medical system, the market is segmented into allopathic, alternative and others. On the basis of route of administration, the market is segmented into oral, injectable and others. On the basis of end-user, the market is segmented into hospitals and private.

By drug class, the hepatitis C drugs market trends fragment represented around 66.2% portion of the general market esteem in 2015. By circulation channel, the medical clinic drug stores fragment is assessed to represent the most elevated portion of the overall industry of 42.8% of the worldwide hepatitis C therapy market by the 2016 end, while the retail drug stores section is assessed to represent 34.2% piece of the pie in 2016.


Regional Analysis


Around the world, America is the biggest Hepatitis C Drugs Market forecast. Europe is the second-biggest market for Hepatitis C drugs. The created locales market is relied upon to stay stale and even may show negative CAGR because of falling patient numbers. In this manner, the emerging countries' market will show moderate development and is relied upon to get on the created areas. China and India will drive the Asia Pacific locale. Africa is relied upon to be a loafer in the hepatitis C market.


Competitive analysis Within the Industry


Vital participants of the worldwide Hepatitis C Drugs Market incorporate AbbVie Inc., Bristol-Myers Squibb Company, F Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Johnson and Johnson, Kadmon Holdings, Inc. also, Merck and Co., Inc.


The Hepatitis C Drugs Market is combined with a couple of vital participants wherein Gilead Sciences, Inc. contributes around 80.1% of the piece of the pie, producing a greater part of the income from the deals of drugs Harvoni and Sovaldi, followed by Bristol-Myers Squibb Company and AbbVie Inc.


Recent Market Developments


In 2018, Gilead Sciences Company sent off nonexclusive interpretations of Harvoni and Epclusa, which was regarded at US$ 24,000 for the full course of treatment. The analysis of these drugs helped with settling the issue associated with the massive cost of marked drugs, which is around US$ 100,000 for the full course of treatment.


In 2016, Organization for Economic Co-movement and Development played out a monetary investigation in Australia that used a numerical model, which depended on the WHO procedure's targets.


Report Overview:


The report for Hepatitis C Drugs Market outlook concentrates on showing the accompanying targets.


Hepatitis C Drugs Market



  • To give a detailed examination of the market structure alongside conjecture for the following 7 years of the different fragments and sub-sections of the Hepatitis C drugs market.

  • To give bits of knowledge about factors influencing the market development.

  • To dissect the market in view of different variables cost examination, inventory network investigation, watchmen five power examination, etc.

  • To give verifiable and figure income of the market fragments and sub-sections concerning four principal geologies and their nations Americas, Europe, Asia-Pacific, and the Middle East and Africa.

  • To give a country-level examination of the market as for the current market size and future forthcoming.

  • To give a country level investigation of the market for fragments by drug class (hostile to viral, immuno-modulators and others), by medication framework (allopathic, option and others), by course of the organization (oral, injectable and others) and by the end client (clinics and private)

  • To give an outline of vital participants and their essential profiling on the lookout, extensively examining their center capabilities, and drawing a cutthroat scene for the market.

  • To follow and break down cutthroat advancements like joint endeavors, vital partnerships, consolidations and acquisitions, new item improvements, and exploration and advancements around the world.



Report Scope:
Report Attribute/Metric Details
  Market Size   USD 281.55 Million
  CAGR   1.17% (2020-2030)
  Base Year   2019
  Forecast Period   2020-2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class, Medicine System, Route of Administration and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Gilead sciences Inc., Abbvie Inc, Johnson & Johnson, Merck & co. Inc., Glaxosmithkline plc, Novartis AG, Bristol-Myers Squibb, Hoffmann-la Roche ltd.
  Key Market Opportunities   Joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments
  Key Market Drivers   disease prevalence, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

hepatitis C drugs market is projected grow at approximately 281.55% CAGR during the assessment period (2020-2030).

Consistent healthcare advancement initiatives and awareness efforts and increasing funding support for R&D from public & private sectors are the major tailwinds pushing the growth of the global hepatitis C drugs market.

North America holds the largest share in the global hepatitis C drugs market, followed by Europe and the Asia Pacific, respectively.

Johnson & Johnson, Gilead Sciences Inc., GSK, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Novartis AG, AbbVie Inc., and Merck & Co. Inc., are some of the major players operating in the hepatitis C drugs market.